Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) have described a new mechanism ...

Novartis has entered a worldwide licensing and partnership agreement with PTC Therapeutics to develop PTC518, a potential oral therapy for Huntington's disease (HD). The PTC518 Huntington's ...

Maze Therapeutics, a kidney disease therapy developer ... MAZE is doing interesting science and I would be interested in seeing how it does in the coming years. I do not like to invest in IPOs ...

About Aquestive Therapeutics, Inc.Aq Reports positive ... bring meaningful improvement to patients' lives through innovative science and delivery technologies, today The headline numbers for ...